CTLA4 and non-small cell lung carcinoma: In the first two cohorts [14, 16], a total of 110 patients with melanoma from the Allen cohort who received anti‐CTLA4 therapy and 75 patients with non‐small‐cell lung cancer (NSCLC) from the Hellmann cohort who received combined anti‐PD‐1 and anti‐CTLA4 therapy were analyzed.